Enters collaboration with the FondaMental Foundation to speed development of diagnostic and therapeutic options for patients
▪ Data provides a biologic rationale to the long-term neuropsychiatric symptoms affecting an important subset of post-COVID-19 patients
▪ Fondation FondaMental and GeNeuro aim to develop one of the first treatment options for these patients

For more information, http://www.geneuro.com/data/news/2021.07.05-PR-GeNeuro-FondaMental-07052021-VF-EN.pdf